Spasticity in multiple sclerosis and role of glatiramer acetate treatment

摘要: Introduction Spasticity is one of the most disabling and difficult-to-treat symptoms shown by patients with multiple sclerosis, who often show a suboptimal unsatisfactory response to classic treatment new available nonpharmacological alternatives. Due progressive nature this condition, early management should be essential improve long-term outcomes. Methods We performed narrative literature review contribution spasticity burden sclerosis potential role disease-modifying drugs. Results Added underlying pathophysiology spasticity, certain external factors drugs such as interferon may exacerbate existing hence their awareness crucial part an effective spasticity. Furthermore, evidence for effectiveness glatiramer acetate in preventing naive those switching from not ignored. Conclusions This proposes examination influence agents on level condition among variables considered when deciding therapy clinical practice.